Cardiac device developer Eko said yesterday it raised $5 million in a Series A round to help support its platform designed for valvular heart disease screening and heart failure monitoring.
The round was led by Artis Ventures and joined by Strategic Partners, DreamIt Ventures, 1812 Ventures and Founder.org, the San Francisco-based company said.
“Eko and Artis Ventures are of likemind in that we both want to tackle the use of technology to improve people’s lives, and for the longest time we’ve relied on the ability for a trained ear to diagnose heart problems. By elegantly applying machine learning to the largest database of sounds, Eko has made it possible for physicians and consumers to imagine a world where we can quickly and easily diagnose medical conditions. While cardiology is a natural starting place, the solutions have extensions to pulmonology and gastroenterology as well, without forcing a change in patient–physician flow. Their solution easily provides a smarter way to track, and diagnose, medical aberrations,” Artis Ventures partner Vasudev Bailey said in a prepared statement.
Eko said that funds from the round will help support the growth of the company’s commercial team and to expand clinical studies of its monitoring and screening platforms.
The company said that its recently FDA cleared Eko Duo device has received appropriate approval to launch a clinical study of the device at UCSF focused on valvular heart disease screenings.
“We partner with investors that are passionate about solving meaningful problems; together we can transform the way clinicians and patients monitor heart disease. This investment will enable us to integrate cardiac decision algorithms into our platform to help physicians better track their patients’ cardiac health,” co-founder & CEO Connor Landgraf said in a press release.
